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Objective. Patients with Sj€ ogren's syndrome (SS) are prone to develop malignant lymphomas, and a correlation has been established between the lymphoproliferations occurring in these disorders and the presence in patients' blood of an unusual B cell population that down-regulates complement receptor 2/CD21. This study was undertaken to identify the B cell compartment from which these lymphoproliferations emerge and determine the mechanisms that promote clonal B cell expansion in patients with SS.
Methods. The reactivity of antibodies expressed by CD19+CD10ÀCD27ÀIgM+CD21
À/low cells isolated from the blood of patients with SS was tested using a polymerase chain reaction-based approach that allows us to clone and express, in vitro, recombinant antibodies produced by single B cells.
Results. Clonal expansions were identified in CD21
À/low B cells isolated from the peripheral blood of 3 patients with SS. These lymphoproliferations expressed B cell receptors (BCRs) that displayed somatic hypermutation lineage trees characteristic of a strong selection by antigens; one of these antigens was identified as a ribosomal self antigen. When the mutated BCR sequences expressed by the expanded CD21
À/low B cell clones from patients with SS were reverted in vitro to their germline counterparts, one clone remained autoreactive.
Conclusion. Clonal lymphoproliferations in patients with SS preferentially accumulate in the autoreactive CD21
À/low B cell compartment often expanded in these subjects, and recognition of self antigens may drive the clonal B cell expansion while further refining BCR self-reactivity. Sj€ ogren's syndrome (SS) is an autoimmune disease characterized by lymphocytic infiltration of the exocrine glands. The frequency of non-Hodgkin's B cell lymphoma is 15-20-fold higher in patients with SS than in the general population (1) . The appearance of lymphoma correlates with an increased proportion of circulating CD19+CD10ÀCD27ÀIgM+CD21
À/low cells, referred to hereinafter as CD21 À/low B cells, suggesting that these B cells may represent the initial reservoir for transformed clones (2) . Consistent with this hypothesis, increased numbers of circulating CD21 À/low B cells have been observed in patients with other autoimmune diseases, including rheumatoid arthritis (RA), and such patients are also prone to develop lymphomas, although at a lower frequency than in patients with SS, further supporting a correlation between CD21 À/low B cells and the emergence of transformed clones (3) . However, monoclonal expansions in the CD21 À/low B cell compartment in patients with SS have not yet been reported. In the present study, we identified 3 patients with SS whose peripheral blood exhibited a monoclonal expansion in their CD21 À/low B cells. In 2 of the SS samples, the lymphoproliferations expressed autoreactive antibodies.
PATIENTS AND METHODS
Patients. We recruited 8 patients with primary SS diagnosed according to the American-European Consensus Group criteria (4) ( Table 1) . Patients provided their signed informed consent prior to the collection of blood samples, in accordance with study protocols approved by the institutional review board.
Single-cell sorting. Mononuclear cells from the blood of healthy donors and patients with SS were enriched for B cells by magnetic separation with CD20 microbeads (Miltenyi Biotech). Prior to purification, the cells were stained with Pacific Blue-conjugated anti-human CD19, PerCP-Cy5.5-conjugated anti-human CD27, phycoerythrin-Cy7-conjugated anti-human CD10, allophycocyanin-conjugated anti-human CD21, and fluorescein isothiocyanate-conjugated anti-human IgM (all from BioLegend). Single cells were sorted on a FACSAria (BD Biosciences) in 96-well polymerase chain reaction (PCR) plates, into CD19+CD21 Synthesis of complementary DNA, amplification of Ig genes, and production and purification of antibodies. RNA from single cells was reverse-transcribed in the original 96-well plates in 12.5-ll reactions containing 100 units of Superscript II reverse trancriptase (RT) (Gibco BRL) for 45 minutes at 42°C. The RT-PCRs, primer sequences, cloning strategy, expression vectors, and methods used for in vitro antibody production and purification have been described previously (5) .
Enzyme-linked immunosorbent assays (ELISAs) and indirect immunofluorescence assays. Analyses of antibody reactivity were performed as described previously, using a highly polyreactive antibody, ED38, as the positive control for assays of HEp-2 cell reactivity and polyreactivity, whereas mnUNGdef05 k50 and mnUNGdef05 j69, which were previously cloned from single mature naive B cells from a patient with uracil N-glycosylase (UNG) deficiency, were used as weak HEp-2-reactive and polyreactive control antibodies (5, 6) . Antibodies were considered polyreactive when they recognized all 3 distinct antigens: double-stranded DNA (dsDNA), insulin, and lipopolysaccharide (LPS). In addition, reactivity to Ro 52 and reactivity to rheumatoid factor were each assessed by a specific ELISA, in which the plates were coated with 1 lg/ml Ro 52 (Sigma-Aldrich) or 1 lg/ml rabbit IgG revealed by peroxidase-conjugated rabbit anti-human IgG (Jackson ImmunoResearch)
For indirect immunofluorescence assays, HEp-2 cellcoated slides (Bion Enterprises) were incubated in a moist chamber at room temperature with purified recombinant antibodies at 50-100 lg/ml, in accordance with the manufacturer's instructions.
Strategy for reverting mutated antibodies to their unmutated counterpart. Using a multitemplate PCR strategy, germline V H and J H templates were first amplified with overlapping, reverted third complementarity-determining region (CDR3) primers combined with primers annealing with either upstream germline V H genes or downstream J H segments. A second PCR fused the 2 overlapping V H and J H PCR fragments, thus generating germline revertant antibody sequences (7) .
Immunoprecipitation and end-labeling of associated RNAs. Five micrograms of each monoclonal antibody was coupled to SureBeads protein G magnetic beads (Bio-Rad) for 30 minutes in phosphate buffered saline (PBS) at room temperature, with rotation. Beads were washed once in PBS, pH 7.4, and then equilibrated in NET-2 lysis buffer (50 mM Tris HCl [pH 7.4], 150 mM NaCl, 1 mM MgCl 2 , 0.5% Nonidet P40). Cell lysates, prepared in NET-2 containing 19 complete protease inhibitors (Roche), 100 lM phenylmethylsulfonyl fluoride, and 200 units/ml RNase OUT (Invitrogen), were added to the beads and incubated for 30 minutes. The beads were then washed 3 times in 750 ll of NET-2, transferred to new microcentrifuge tubes, and washed an additional 3 times. Beads were then resuspended in 350 ll NET-2, 2 ll glycogen, 5 ll 20% sodium dodecyl sulfate, and 40 ll NaOAc. The resuspended beads were then extracted twice with acid phenol:chloroform:isoamyl alcohol (25:24:1, volume/volume), and the nucleic acids were precipitated from the aqueous phase with a 2.5 volume of ethanol. T4 RNA ligase was used to end-label the precipitated RNA with [ 32 P]-cytidine-3 0 ,5 0 -bisphosphate, overnight at 4°C. Labeled RNAs were then resolved on a 5% polyacrylamide-7M urea gel. Gels were dried, exposed on Fujifilm imaging plates, and visualized with a Typhoon imager system (GE Healthcare).
Statistical analysis. Statistical analysis was performed using GraphPad Prism software (version 5.0). Differences between groups were analyzed for statistical significance using a nonparametric Mann-Whitney test. P values less than or equal to 0.05 were considered significant.
RESULTS

Accumulation of monoclonal expansions in CD21
À/low B cells from patients with SS. To determine the B cell compartment from which clonal lymphoproliferations either originated or colonized in the peripheral blood of patients with SS, we analyzed samples from 4 patients with SS in addition to 4 samples from a previously reported cohort of patients with SS (2, 5) to amplify the expression of Ig genes in CD21 À/low B cells and CD19+CD10À CD27ÀIgM+CD21+ mature naive B cells (Table 1) . Samples from 5 of the patients with SS (identified as patients SS01, SS201, SS03, SS204, and SS59 in Table 1 ) showed enhanced frequencies of peripheral CD21 À/low B cells, whereas only a few peripheral CD21 À/low B cells were found in the blood of healthy donors (3) ( Figure 1A ).
Analyses of Ig sequences revealed the presence of monoclonal expansions in CD21 À/low B cells from 3 of the 5 patients. In patients SS204 and SS59, clonal sequences accounted for 98% and 85% of the isolated CD21 À/low B cells, respectively, whereas in patient SS03, all of the CD21 À/low B cells corresponded to an expanded clone (Figure 1B; see also Supplementary  Tables 1-3, available on À/low B cells. Strong antigen-specific selection revealed by the monoclonal expansion Ig sequences. We then analyzed the characteristics of the antibodies expressed by the monoclonal expansions of B cells from the blood of patients with SS. The expanded clones from all 3 SS samples expressed antibodies with mutated heavy-chain and lightchain genes, revealing that they originated from antigenstimulated B cells (Figures 2 and 3) . The preferential accumulation of replacement mutations in heavy-chain CDR regions of the expanded clonal B cells (CDR2 in sample SS03 and CDR1 in sample SS204) further supports the notion that antigenic selection pressure is occurring during these expansions (Figures 2A and B) . In addition, the identification of related heavy-chain gene sequences with different numbers of mutations in the 3 clonal expansions also suggests that antigenic selection is ongoing (Figures 2A and B) . This was especially evident in the clonal expansion of B cells from patient SS03, in which clone H16 from the mature naive B cell compartment displayed only 8 mutations in its heavy chain, all of which were shared by the related clones that contained 12 additional mutations (Figures 2A and B) . Of note, the expanded clone from patient SS59 contained the lowest numbers of mutations in both heavy-chain and light-chain genes, and this correlated with a modestly expanded CD21
À/low B cell population (Figures 2A and B) , suggesting that the lymphoproliferation and expansion began more recently in this patient than in the other 2 patients with SS.
Lineage tree analysis of the heavy chains expressed during SS clonal expansions revealed linear and poorly branched mutation acquisition patterns, suggesting that strong antigen-specific selection occurs (8) (Figure 2B ). The j-chains in the expanded clones from patients SS03 and SS204 also displayed intraclonal diversification with poorly branched lineage trees ( Figures 3A and B) . Strong antigenic selection was further evidenced by elevations in the replacement-to-silence mutation ratios in the CDRs, and sometimes in the framework regions, of the heavy chains and j-chains expressed by these lymphoproliferations ( Figures 2C and 3C ). These findings support the conclusion that clonal expansions in patients with SS appear to be driven by strong antigenic stimulation.
Expression of potentially autoreactive antibodies by the monoclonal expansion of B cells in patients with SS. To determine the nature of the antigens that may drive lymphoproliferation, we tested the reactivity of the antibodies expressed by the monoclonal expansions of B cells in patients with SS. Since CD21 À/low B cells are enriched in autoreactive clones (2), we performed ELISAs to assess their reactivity toward human HEp-2 cells and their potential multispecificity/polyreactivity (5). We found that in 2 of the 3 SS blood samples in which lymphoproliferations were evident, mutated recombinant antibodies cloned from samples SS59 and SS03 were autoreactive ( Figure 4A ). SS59 clones were highly HEp-2-reactive and polyreactive and recognized nuclear antigens (Figures 4A-C) . Mutated antibodies arising from the SS03 clonal expansion were weakly HEp-2-reactive and polyreactive, as validated by comparisons with mnUNGdef05 k50, a low HEp-2-positive control antibody, and mnUNGdef05 j69, a low polyreactivepositive control antibody, respectively (6) ( Figures 4A and  C) . Antibodies from the SS204 sample were not HEp-2-reactive or polyreactive, although some weak reactivity below the values for the low-positive control was detected for dsDNA and LPS antigens ( Figures 4A and C) . Since Ro 52 is a major self antigen in SS, and antiIgG rheumatoid factor reactivity has been suggested to be associated with lymphomas (9), we tested the SS lymphoproliferations for reactivity to these antigens ( Figure 4D ). Consistent with their aforementioned polyreactivity, SS59 clones and, to a lesser extent, SS03 clones displayed reactivity to Ro 52 and rheumatoid factor, while SS204 clones did not bind these self antigens ( Figure 4D ).
Because some prominent autoantigens in patients with SS, such as Ro 60, La, Sm, and RNP, consist of proteins complexed with small noncoding RNAs (10), we explored whether the self antigens recognized by SS lymphoproliferations included these RNAs. To determine this, we performed immunoprecipitations on human keratinocytes with these recombinant antibodies and examined the RNAs present in the immunoprecipitates. Although we did not detect the characteristic noncoding RNAs associated with these autoantigens, antinuclear antibodies from SS59 mutated clones recognized an antigen associated with 5S and 5.8S ribosomal RNAs (rRNAs), revealing that these antibodies may harbor antiribosomal reactivity ( Figure 5) . Antibodies from the SS03 and SS204 clones did not immunoprecipitate small RNAs ( Figure 5 ). Taken together, these findings indicate that in 2 of the 3 SS samples displaying lymphoproliferations, autoreactive antibodies that cross-react with Ro 52 were expressed and rheumatoid factor reactivity was a shared feature. Furthermore, in 1 of the SS samples, a ribosomal antigen associated with 5S and 5.8S rRNAs was recognized.
Autoreactive B cell origin of the lymphoproliferations in patients with SS. To determine whether the autoreactive monoclonal B cell expansions in patients with SS were derived from unmutated self-reactive clones that acquired somatic hypermutation (SHM), we reverted in vitro-mutated antibody heavy-chain and light-chain genes to their original unmutated sequences (see Supplementary Figure 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/ art.40352/abstract) (7). Because Ig heavy-chain CDR3 regions play an essential role in conferring antibody polyreactivity and, potentially, autoreactivity (11), we designed primers to revert CDR3 sequences, referred to hereinafter as revertants, thereby allowing for conservative, and sometimes more extended, reversion scenarios for these antibodies (see Supplementary Figure 1) . We then tested the revertant reactivities by ELISA and immunofluorescence assays, and compared their reactivities to those of their mutated counterparts (Figure 4) . The reverted antibody from SS59 monoclonal expansions retained HEp-2 reactivity (Figure 4A ), suggesting that this lymphoproliferation may originate from an intrinsically self-reactive B cell.
Consistent with this hypothesis, the SS59 revertant also remained polyreactive and retained Ro 52 and rheumatoid factor reactivity, although this unmutated antibody bound dsDNA, insulin, and LPS with decreased affinity (Figures 4C and D) . However, we found that SHM was responsible for the antinuclear reactivity of sample SS59, because the SS59 revertant did not stain nuclear structures and did not enrich for 5S and 5.8S rRNAs in immunoprecipitations ( Figures 4B and 5) . Revertants from samples SS03 and SS204 showed weak reactivity against some of the tested antigens. SS03 revertants were borderline HEp-2-reactive but were not polyreactive and did not bind Ro 52 or IgG (Figure 4 ). Although SS204 revertants were not HEp-2-reactive, some of them displayed weak reactivity for insulin, Ro 52, and rheumatoid factor (Figure 4) . We conclude that lymphoproliferations in CD21 À/low B cells from patients with SS often express autoreactive antibodies, and these may originate from B cell clones activated by self antigens. This process may promote the proliferation of B cells and the acquisition of SHM, thereby enhancing the B cell receptor (BCR) affinity for self.
DISCUSSION
We showed that the lymphoproliferations occurring in the peripheral blood of patients with SS accumulate in the CD21 À/low B cell compartment and are often characterized by the expression of autoreactive antibodies. Non-Hodgkin's B cell lymphoma occurs frequently in patients with SS, and its occurrence is reportedly correlated with the proportion of CD21 À/low B cells in the patient's blood (2, 12, 13) . In addition, patients with other autoimmune diseases, including RA and systemic lupus erythematosus, or those with chronic infections are also prone to develop lymphomas, although at a lower frequency than in SS, and display increased numbers of CD21 À/low B cells in their blood, further supporting the notion of a correlation between CD21 À/low B cells and the emergence of transformed clones (3, 9, 14) .
By studying samples from patients with SS in which the frequency of CD21 À/low B cells was at least 30% in the CD19+CD27À peripheral B cell compartment, we identified 3 patients who displayed monoclonal expansions in their blood. All 3 patients with SS showed the highest frequency of expanded clones in their CD21 À/low B cells, suggesting that the monoclonal expansions may originate from this compartment. Consistent with this hypothesis, the lymphoproliferation occurring in 1 of the SS samples was restricted to CD21 À/low B cells and was not detected in other B cell compartments, including new emigrant/ transitional and mature naive B cells. Of note, samples SS1003 and SS201, both of which were from patients with mucosa-associated lymphoid tissue lymphoma, displayed only a modest increase in the frequency of CD21 À/low B cells. However, both of these patients had been treated with rituximab, a medication that depletes B cells; therefore, their treatment likely led to alterations in the frequency of CD21 À/low B cells in their blood. Since CD21 À/low B cells from patients with SS and patients with RA often express autoreactive antibodies, it is likely that these cells may contain self-reactive precursors of lymphoproliferation (2,3) .
However, the detection of monoclonal expansions in mature naive B cells from 2 of the patients with SS may challenge this scenario. Our findings suggest that lymphoproliferations could emerge from this peripheral B cell compartment, which is also enriched in autoreactive clones (15) . Consistent with this hypothesis, a precursor clone (H16) was identified in mature naive B cells that displayed a heavy chain with only 8 mutations, whereas all other related clones from mature naive and CD21 À/low B cells harbored 12 additional mutations. Therefore, lymphoproliferative clones may originate from activated mature naive B cells and then preferentially develop and accumulate in the CD21
À/low B cell compartment. However, we cannot exclude the possibility that the detection of expanded clones in mature naive B cells might be attributed to the suboptimal gating strategies that were utilized to distinguish CD21 À/low B cells from CD21+ mature naive B cells, since all other cell surface markers used to identify these 2 B cell subpopulations are the same. Indeed, the overwhelming expansion of transformed clones expressing low levels of surface CD21 may contribute to their detection in CD21-expressing mature naive B cells. Additional studies are therefore warranted to determine whether B cell lymphomas in patients with SS originate either from mature naive B cells or from CD21 À/low B cells, both of which are enriched in autoreactive clones.
An interesting line of inquiry is to determine what mechanisms preside over the emergence of B cell lymphomas accumulating in the CD21 À/low B cell compartment. Intrinsic and extrinsic B cell mechanisms likely contribute to the development of lymphomas in patients with SS. Long-term stimulation of BCRs by self antigens may favor the malignant transformation of CD21 À/low B cells (5, 8) . Consistent with this hypothesis, we found that expanded B cell clones from 2 of the 3 patients with SS expressed mutated autoreactive BCRs, whereas antibodies expressed by expanded B cells from patient SS204 did not appear to be autoreactive. The poorly branched trees, reflecting the linear SHM acquisition history of the lymphoproliferations identified in all 3 patients with SS, suggest a strong antigen-specific selection in which rare SHM events that increase BCR self-reactivity are highly selected (8) . The putative unmutated germline clones from which the 3 mutated SS B cell expansions originated displayed either decreased or no self-reactivity in comparison to their mutated counterparts, suggesting that SHM did increase self-reactivity in both lymphoproliferations in which autoreactive BCRs were expressed.
BCR self-reactivity seems to be a common feature shared by many B cell lymphomas, including chronic lymphocytic lymphomas and diffuse large B cell lymphomas (7, 16) . In diffuse large B cell lymphomas, BCRs have been reported to recognize dying cells or DNA (16) (17) (18) . BCR self-reactivity is critical for the survival and maintenance of transformed B cell clones, because replacement by nonautoreactive BCRs induced clonal death (16) . BCR self-reactivity is also associated with the emergence of chronic lymphocytic lymphomas, being characterized by the emergence of clones that retain strong self-reactive BCR features and that are associated with worse prognoses in patients (7) . The recognition of nuclear antigens, such as ribosomal structures, as observed herein in the B cell expansions in patient SS59, may facilitate the activation and proliferation of B cells, because these self antigens contain RNAs that provide BCR costimulatory signals through binding of Toll-like receptor 7 (TLR-7) (19) .
Similarly, rheumatoid factor reactivity, which has been identified in salivary gland lymphomas or inferred on the basis of CDR3 homology, may also be a factor contributing to the TLR-7-driven activation of clonally expanded B cells in patients with SS, since a common feature in the serum of patients with SS is the binding of the clonally expanded BCRs to IgG immune complexes that contain small noncoding RNAs (20, 21) . TLR-7/BCR coligation induces the expression of Axl in B cells, which may favor the formation or recruitment of these activated B cells in tertiary lymphoid structures (22) . Lymphomas in patients with SS, usually found in the mucosal tissue, may initially develop in a salivary gland from a cluster of proliferating B cells that seed tertiary lymphoid structures, thereby offering a favorable environment for B cell expansion by providing Tcell help and BAFF (9, 23, 24) .
Indeed, BAFF is important for B cell survival, and its concentration is elevated in the serum and salivary glands of patients with SS (25) . Since CD21 À/low B cells are dependent on BAFF for their survival, anti-BAFF therapy may be beneficial in patients with SS, by affecting the survival of proliferating B cells (26) . Alternatively, and despite the heterogeneous efficacy of anti-B cell therapy 306 GLAUZY ET AL in patients with SS, anti-CD20 therapy may be considered, since it has the capacity to eliminate CD21 À/low B cells, including potentially premalignant clonal B cell expansions that display high expression of CD20. Additional analyses could clarify which regimen may be more beneficial to thwart autoimmune features and eliminate clonal B cell lymphoproliferations in patients with SS.
